ADMA Biologics Inc vs Lithium Americas Corp — how do they compare? ADMA Biologics Inc trades at $9.87 (market cap $2.22B), while Lithium Americas Corp trades at $3.29 (market cap $1.18B). The key difference: ADMA Biologics Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| ADMA | LAC | |
|---|---|---|
Market Cap | $2.22B | $1.18B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $10.05 |
52-Week Low | $7.60 | $2.71 |
Enterprise Value | $2.29B | $1.29B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lithium Americas Corp. (LAC) trades at $3.30, up 1.54% today, with a bullish technical signal from moving averages but negative profitability metrics including an ROE of -11.35% and net loss of $122.09 million in 2025. Recent news highlights a $175 million financing to strengthen the balance sheet as Thacker Pass approaches peak construction, though earnings have been volatile with mixed quarterly beats and misses.
The outlook is balanced: analyst consensus shows 47% buy ratings with no sells, reflecting optimism on lithium demand, but high execution risk remains given negative cash flow from operations and substantial capital needs. Upside depends on successful project development, while downside risks include funding pressures and commodity price volatility.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →